Pfizer COVID-19 Vaccine Trial Diversity Slips As Enrollment Rises, Unlike Moderna
Trial diversity is among the issues that stakeholders worry could hinder vaccine uptake.
You may also be interested in...
BIO head Michelle McMurry-Heath discusses group’s efforts to increase enrollment of people of color in COVID-19 clinical trials and why New York’s task force to give second review to COVID-19 vaccines is “dangerous for patients.”
Effectiveness can be evaluated more quickly because researchers won’t have to wait for the second dose, company executive notes during briefing on the launch of the Phase III study.
ACIP defers vote on who should be inoculated first until it has data on a specific product, but vaccine acceptance among different groups could be weighed as factor in setting distribution priorities, committee members suggest.